Abstract
Abstract
Background
Regulatory authorities register medicines for patients to access them within a reasonable period of time. There is a paucity of available data regarding the extent to which registered medicines reach the public after market authorisation is granted by the South African Health Products Regulatory Authority (SAHPRA). This is important since time spent by SAHPRA assessing medicines that are subsequently not launched onto the South African market means time wasted, which could be spent on assessing new medicines that address an unmet need in the country. Consequently, we initially analysed the time taken for registered medicines to reach patients and the relationship between medicines registered at SAHPRA and those subsequently dispensed in private pharmacies. The extent of registration of multiple sourced versus new patented medicines was also explored.
Methods
A retrospective, descriptive and quantitative investigation was conducted for medicines registered between 2014 and 2019. Registered and dispensed medicines were compared to establish accessibility post registration. Data sources included SAHPRA and IQVIA datasets. Microsoft Excel and SAS were used for data storage, analysis, and computation of descriptive statistical analysis.
Results
Of (N = 2175) registered medicines, only 358 (16.5%; 95% CI 15.0%—18.1%) were dispensed to patients, and out of 1735 medicines registered between 2015 and 2019, only 57 (3.3%; 95% CI 2.5%—4.2%) were dispensed during the study period. Medicines acting on the central nervous system were registered and dispensed the most at 21.0% and 18.0%, respectively, whereas antineoplastic and immunomodulation agents were registered and dispensed only 11% and 5%, respectively. A concern was that only 13.0% of registered medicines were originators, with most either as generics, including branded generics, or pseudo-generics.
Conclusion
Regulatory measures should be implemented to ensure increased medicine access post-registration for new originators, especially for priority disease areas that benefit patients. Mental health diseases and improved access to oncology medicines require special attention and further investigation in South Africa.
Funder
National Research Foundation,South Africa
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference51 articles.
1. Narsai K, Leufkens, H G M and Mantel‑Teeuwisse A K . Linking market authorizations of medicines with disease burden in South Africa. Journal of Pharmaceutical Policy and Practice. 2021. Available on https://joppp.biomedcentral.com/track/pdf/https://doi.org/10.1186/s40545-021-00314-x.pdf.
2. Kanavos P, MacLehose L, McKee M. Border-crossing patients GATS and health services Fair trade: health and safety Movement of health professionals Beyond the candidate countries: health and the stability pact countries. Gateway to the European Union: health and EU enlargement. Euro health, (Autumn 2002) Volume8 Number 4, Special Issue, Autumn 2002 ISSN1356–1030. Euro Health. Available from: https://www.lse.ac.uk/lse-health/assets/documents/eurohealth/issues/eurohealth-v8n4.pdf#page=28.
3. Narsai K, Williams A, Mantel-Teeuwisse AK. Impact of regulatory requirements on medicine registration in African countries – perceptions and experiences of pharmaceutical companies in South Africa. Southern Med Review. 2012;5(1):31–7 Available from: (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471191/pdf/smr-05-031.pdf).
4. Prašnikar J, Škerlj T. New product development process and time-to-market in the generic pharmaceutical industry. Ind Mark Manag. 2006;35(6):690–702 Available from: (https://www.sciencedirect.com/science/article/pii/S0019850105000817).
5. Sithole T, Mahlangu G, Salek S, Walker S. Evaluating the Success of ZaZiBoNa, the Southern African Development Community Collaborative Medicines Registration Initiative. Ther Innov Regul Sci. 2020;54(6):1319–29. https://doi.org/10.1007/s43441-020-00154-y. Epub 2020 Apr 29.